The prognostic impact of monoclonal immune globulin and free light chain secretion in diffuse large B cell lymphoma (DLBCL). Issue 5 (15th April 2020)

• Record Type: Journal Article
• Authors: Maiolo, Elena; Alma, Eleonora; Napodano, Cecilia; Gulli, Francesca; Bellesi, Silvia; Cuccaro, Annarosa; Pocino, Krizia; D'Alo', Francesco; Iachini, Marco; Martini, Maurizio; Larocca, Luigi Maria; De Stefano, Valerio; Basile, Umberto; Hohaus, Stefan
• Is Part Of: Leukemia & lymphoma. Volume 61:Issue 5(2020)
• Page Start: 1133
• Page End: 1139
• Publication Date: 2020-04-15
• Subjects: Diffuse large B-cell lymphoma -- free light chain -- monoclonal immune globulin -- prognosis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1706731
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: We analyzed the prognostic impact of levels of free light chains (FLC) in 106 patients with DLBCL, selecting 61 patients with a monoclonal (M) protein in serum, and 45 patients without a M protein as an IPI-matched control group. Patients with a M protein had higher levels of FLC, but these were not of prognostic significance in this group. The presence of a M protein nullified associations of κ-FLC with several laboratory parameters indicating immune system activation observed in patients without a M protein. Patients without M protein and κ-FLC >50 mg/L had a significant inferior event-free survival ( p = .004). The presence of M protein of an IgM type at diagnosis was a negative outcome predictor ( p = .008), while a non-IgM M protein did not significantly impact on prognosis. In conclusion, the prognostic performance of the FLC assay is altered by the presence of a M protein.